The European Union has reached an agreement to overhaul its pharmaceutical legislation, aiming to improve patient access to medicines and enhance the competitiveness of the life sciences sector. Key features include extended data protection and market exclusivity for manufacturers, with incentives for developing innovative therapies for unmet medical needs. While some groups express concerns about high protections, lawmakers emphasize the need for new treatments and the introduction of a system to support antibiotic development.